Benjamin B Gelman

List of Publications by Year
in descending order

111 papers	7,247 citations	87888 38 h-index	60623 81 g-index
111 all docs	111 docs citations	111 times ranked	5685 citing authors

#	Article	IF	Citations
1	HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of NeuroVirology, 2011, 17, 3-16.	2.1	1,327
2	Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System. Archives of Neurology, 2008, 65, 65.	4.5	777
3	Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virusâ€"Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy. Archives of Neurology, 2010, 67, 552.	4.5	347
4	Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study. Clinical Infectious Diseases, 2015, 60, 473-480.	5.8	326
5	Interrater Reliability of Clinical Ratings and Neurocognitive Diagnoses in HIV. Journal of Clinical and Experimental Neuropsychology, 2004, 26, 759-778.	1.3	284
6	Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology, 2014, 82, 2055-2062.	1.1	255
7	Clinical factors related to brain structure in HIV: the CHARTER study. Journal of NeuroVirology, 2011, 17, 248-57.	2.1	158
8	Chronic-Pain-Associated Astrocytic Reaction in the Spinal Cord Dorsal Horn of Human Immunodeficiency Virus-Infected Patients. Journal of Neuroscience, 2012, 32, 10833-10840.	3.6	152
9	The National NeuroAIDS Tissue Consortium Brain Gene Array: Two Types of HIV-Associated Neurocognitive Impairment. PLoS ONE, 2012, 7, e46178.	2.5	150
10	Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Annals of Neurology, 2008, 64, 566-572.	5.3	147
11	Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered. Current HIV/AIDS Reports, 2015, 12, 272-279.	3.1	130
12	Low atazanavir concentrations in cerebrospinal fluid. Aids, 2009, 23, 83-87.	2.2	112
13	Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. Journal of NeuroVirology, 2016, 22, 170-178.	2.1	112
14	Neurovirological Correlation With HIV-Associated Neurocognitive Disorders and Encephalitis in a HAART-Era Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 487-495.	2.1	111
15	Cerebral Î²-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE Îµ4 carriers. Aids, 2012, 26, 2327-2335.	2.2	95
16	Amoebic Encephalitis Due to Sappinia diploidea. JAMA - Journal of the American Medical Association, 2001, 285, 2450.	7.4	93
17	Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. Journal of Antimicrobial Chemotherapy, 2011, 66, 354-357.	3.0	82
18	Prefrontal Dopaminergic and Enkephalinergic Synaptic Accommodation in HIV-associated Neurocognitive Disorders and Encephalitis. Journal of NeuroImmune Pharmacology, 2012, 7, 686-700.	4.1	78

#	Article	IF	Citations
19	Gp120 in the pathogenesis of human immunodeficiency virusâ€“associated pain. Annals of Neurology, 2014, 75, 837-850.	5.3	76
20	Pathology and pathogenesis of sensory neuropathy in Friedreichâ€™s ataxia. Acta Neuropathologica, 2010, 120, 97-108.	7.7	72
21	Low Cerebrospinal Fluid Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 376-381.	2.1	72
22	Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 105-113.	4.0	67
23	Diffuse microgliosis associated with cerebral atrophy in the acquired immunodeficiency syndrome. Annals of Neurology, 1993, 34, 65-70.	5.3	65
24	MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology. PLoS Pathogens, 2017, 13, e1006360.	4.7	65
25	Abnormal Striatal Dopaminergic Synapses in National NeuroAIDS Tissue Consortium Subjects with HIV Encephalitis. Journal of NeuroImmune Pharmacology, 2006, 1, 410-420.	4.1	64
26	Brain aging in acquired immunodeficiency syndrome: Increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation. Journal of NeuroVirology, 2004, 10, 98-108.	2.1	62
27	Pulmonary Tuberculosis in Humanized Mice Infected with HIV-1. Scientific Reports, 2016, 6, 21522.	3.3	62
28	Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders. Journal of Clinical Investigation, 2014, 124, 4459-4472.	8.2	62
29	Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV. Journal of NeuroVirology, 2016, 22, 431-441.	2.1	61
30	Acquired neuronal channelopathies in HIV-associated dementia. Journal of Neuroimmunology, 2004, 157, 111-119.	2.3	58
31	Synaptic Proteins Linked to HIV-1 Infection and Immunoproteasome Induction: Proteomic Analysis of Human Synaptosomes. Journal of NeuroImmune Pharmacology, 2010, 5, 92-102.	4.1	55
32	Morphometry, histopathology, and tomography of cerebral atrophy in the acquired immunodeficiency syndrome. Annals of Neurology, 1992, 32, 31-40.	5.3	54
33	Neuropathological and Ultrastructural Features of Amebic Encephalitis Caused bySappinia diploidea. Journal of Neuropathology and Experimental Neurology, 2003, 62, 990-998.	1.7	51
34	Persistent Hijacking of Brain Proteasomes in HIV-Associated Dementia. American Journal of Pathology, 2010, 176, 893-902.	3.8	49
35	Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1093-1118.	1.7	46
36	Astrocyte Elevated Gene-1 Is a Novel Modulator of HIV-1-associated Neuroinflammation via Regulation of Nuclear Factor-ÎºB Signaling and Excitatory Amino Acid Transporter-2 Repression. Journal of Biological Chemistry, 2014, 289, 19599-19612.	3.4	43

#	Article	IF	Citations
37	Friedreich Ataxia: Developmental Failure of the Dorsal Root Entry Zone. Journal of Neuropathology and Experimental Neurology, 2017, 76, 969-977.	1.7	43
38	The effect of lead on oxidative hemolysis and erythrocyte defense mechanisms in the rat. Toxicology and Applied Pharmacology, 1978, 45, 119-129.	2.8	40
39	Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology, 2015, 84, 241-250.	1.1	40
40	Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. Journal of NeuroVirology, 2013, 19, 393-401.	2.1	38
41	Quantitative neuropathology associated with chronic manganese exposure in South African mine workers. NeuroToxicology, 2014, 45, 260-266.	3.0	38
42	CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. Journal of NeuroVirology, 2015, 21, 559-567.	2.1	36
43	Potential Role for White Matter Lysosome Expansion in HIV-Associated Dementia. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 422-425.	2.1	35
44	The Cerebrospinal Fluid HIV Risk Score for Assessing Central Nervous System Activity in Persons With HIV. American Journal of Epidemiology, 2014, 180, 297-307.	3.4	35
45	Substance abuse increases the risk of neuropathy in an HIVâ€infected cohort. Muscle and Nerve, 2012, 45, 471-476.	2.2	34
46	Wnt Signaling in the Pathogenesis of Human HIV-Associated Pain Syndromes. Journal of NeuroImmune Pharmacology, 2013, 8, 956-964.	4.1	34
47	Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. Journal of Antimicrobial Chemotherapy, 2013, 68, 684-689.	3.0	34
48	Heme oxygenase-1 promoter region (GT)n polymorphism associates with increased neuroimmune activation and risk for encephalitis in HIV infection. Journal of Neuroinflammation, 2018, 15, 70.	7.2	33
49	The role of chemokine C-C motif ligand 2 genotype and cerebrospinal fluid chemokine C-C motif ligand 2 in neurocognition among HIV-infected patients. Aids, 2015, 29, 1483-1491.	2.2	32
50	Spinal Cord Ventral Horns and Lymphoid Organ Involvement in Powassan Virus Infection in a Mouse Model. Viruses, 2016, 8, 220.	3.3	31
51	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. Journal of Infectious Diseases, 2016, 213, 1065-1073.	4.0	31
52	BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism. Journal of Neuroscience, 2018, 38, 4288-4300.	3.6	31
53	Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. Journal of Neuroinflammation, 2017, 14, 72.	7.2	30
54	Genetic Variation in Iron Metabolism Is Associated with Neuropathic Pain and Pain Severity in HIV-Infected Patients on Antiretroviral Therapy. PLoS ONE, 2014, 9, e103123.	2.5	29

#	Article	IF	Citations
55	HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via Î²-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. American Journal of Pathology, 2017, 187, 91-109.	3.8	29
56	Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States. Journal of the International Neuropsychological Society, 2018, 24, 163-175.	1.8	29
57	Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. Journal of the International Neuropsychological Society, 2019, 25, 507-519.	1.8	28
58	HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. Journal of NeuroVirology, 2014, 20, 209-218.	2.1	27
59	Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clinical Infectious Diseases, 2015, 61, 1476-1484.	5.8	27
60	Host genetic polymorphisms in human immunodeficiency virusâ€“related neurologic disease. Journal of NeuroVirology, 2004, 10, 67-73.	2.1	26
61	Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. Journal of NeuroVirology, 2016, 22, 479-487.	2.1	26
62	Genomeâ€wide association study of HIVâ€associated neurocognitive disorder (HAND): A CHARTER group study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 413-426.	1.7	26
63	Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity. Neurobehavioral HIV Medicine, 2013, 5, 11.	2.0	25
64	Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. Journal of NeuroVirology, 2012, 18, 511-520.	2.1	24
65	Concurrent Classification Accuracy of the HIV Dementia Scale for HIV-Associated Neurocognitive Disorders in the CHARTER Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 36-42.	2.1	24
66	Macrophage Apolipoprotein Synthesis and Endoneurial Distribution as a Response to Segmental Demyelination. Journal of Neuropathology and Experimental Neurology, 1991, 50, 383-407.	1.7	23
67	Degradation of heme oxygenaseâ€1 by the immunoproteasome in astrocytes: A potential interferonâ€Î³â€dependent mechanism contributing to HIV neuropathogenesis. Glia, 2017, 65, 1264-1277.	4.9	23
68	Human Microglial Cell Isolation from Adult Autopsy Brain: Brain pH, Regional Variation, and Infection with Human Immunodeficiency Virus Type 1. Journal of NeuroVirology, 2003, 9, 346-357.	2.1	20
69	Frailty in medically complex individuals with chronic HIV. Aids, 2019, 33, 1603-1611.	2.2	20
70	Epigenetic Suppression of HIV in Myeloid Cells by the BRD4-Selective Small Molecule Modulator ZL0580. Journal of Virology, 2020, 94, .	3.4	20
71	White Matter Abnormalities Linked to Interferon, Stress Response, and Energy Metabolism Gene Expression Changes in Older HIV-Positive Patients on Antiretroviral Therapy. Molecular Neurobiology, 2020, 57, 1115-1130.	4.0	19
72	Lipocalin-2 mediates HIV-1 induced neuronal injury and behavioral deficits by overriding CCR5-dependent protection. Brain, Behavior, and Immunity, 2020, 89, 184-199.	4.1	19

#	Article	IF	Citations
73	Lentiviral Infections Persist in Brain despite Effective Antiretroviral Therapy and Neuroimmune Activation. MBio, 2021, 12, e0278421.	4.1	19
74	Oncocytoma in Melanocytoma of the Spinal Cord: Case Report. Neurosurgery, 2000, 47, 756-759.	1.1	16
75	Increased vulnerability to demyelination in streptozotocin diabetic rats. , 1996, 373, 55-61.		15
76	Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. Journal of NeuroVirology, 2012, 18, 81-90.	2.1	15
77	Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV,the, 2019, 6, e456-e462.	4.7	15
78	Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. Journal of the International Neuropsychological Society, 2020, 26, 147-162.	1.8	15
79	Neonatal lead toxicity andin vitrolipid peroxidation of rat brain. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1979, 5, 671-682.	2.3	14
80	Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2012, 56, 1985-1989.	3.2	14
81	Characteristics of Motor Dysfunction in Longstanding Human Immunodeficiency Virus. Clinical Infectious Diseases, 2020, 71, 1532-1538.	5.8	14
82	Heme oxygenase-1 promoter (GT) _n polymorphism associates with HIV neurocognitive impairment. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	14
83	Multimorbidity networks associated with frailty among middle-aged and older people with HIV. Aids, 2021, 35, 2451-2461.	2.2	14
84	Apolipoprotein E Îµ4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. Journal of NeuroVirology, 2016, 22, 607-614.	2.1	13
85	Brain lipofuscin concentration and oxidant defense enzymes in leadâ€poisoned neonatal rats. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1979, 5, 683-698.	2.3	12
86	Small Animal Model of Post-chemotherapy Tuberculosis Relapse in the Setting of HIV Co-infection. Frontiers in Cellular and Infection Microbiology, 2020, 10, 150.	3.9	12
87	A neuron-to-astrocyte Wnt5a signal governs astrogliosis during HIV-associated pain pathogenesis. Brain, 2022, 145, 4108-4123.	7.6	12
88	Quantifying Apoptosis in Banked Human Brains Using Flow Cytometry. Journal of Neuropathology and Experimental Neurology, 1996, 55, 1164-1172.	1.7	11
89	Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology, 2012, 433, 498-505.	2.4	11
90	Potential Roles of Microglial Cell Progranulin in HIV-Associated CNS Pathologies and Neurocognitive Impairment. Journal of NeuroImmune Pharmacology, 2014, 9, 117-132.	4.1	11

#	Article	IF	Citations
91	When do models of NeuroAIDS faithfully imitate â€œthe real thingâ€?. Journal of NeuroVirology, 2018, 24, 146-155.	2.1	11
92	HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin. Cell Death and Differentiation, 2019, 26, 1942-1954.	11.2	11
93	Family History of Dementia Predicts Worse Neuropsychological Functioning Among HIV-Infected Persons. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 316-323.	1.8	10
94	Heart and Nervous System Pathology in Compound Heterozygous Friedreich Ataxia. Journal of Neuropathology and Experimental Neurology, 2017, 76, 665-675.	1.7	8
95	Acrolein and other toxicant exposures in relation to cardiovascular disease among marijuana and tobacco smokers in a longitudinal cohort of HIV-positive and negative adults. EClinicalMedicine, 2021, 31, 100697.	7.1	8
96	Novel Role for Macrophage Galactose-Type Lectin-1 to Regulate Innate Immunity againstMycobacterium tuberculosis. Journal of Immunology, 2021, 207, 221-233.	0.8	8
97	Advancing our understanding of HIV co-infections and neurological disease using the humanized mouse. Retrovirology, 2021, 18, 14.	2.0	8
98	The neuropathology of HIV. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 85, 301-317.	1.8	7
99	Modeling brain lentiviral infections during antiretroviral therapy in AIDS. Journal of NeuroVirology, 2017, 23, 577-586.	2.1	7
100	Predictors of Transition to Frailty in Middle-Aged and Older People With HIV: A Prospective Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 518-527.	2.1	7
101	Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS: Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort. Journal of HIV/AIDS and Social Services, 2014, 13, 8-25.	0.7	6
102	Neuroinflammation associates with antioxidant heme oxygenase-1 response throughout the brain in persons living with HIV. Journal of NeuroVirology, 2020, 26, 846-862.	2.1	6
103	The significance of intercalated discs in the pathogenesis of Friedreich cardiomyopathy. Journal of the Neurological Sciences, 2016, 367, 171-176.	0.6	5
104	Incarceration and the acquired immunodeficiency syndrome: Autopsy results in Texas prison inmates. Human Pathology, 1996, 27, 1282-1287.	2.0	4
105	Lower CSF A? is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Current HIV Research, 2016, 14, 324-330.	0.5	4
106	Primary Langerhans cell histiocytosis of the lacrimal gland in an adult. Canadian Journal of Ophthalmology, 2015, 50, e40-e43.	0.7	3
107	Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy. Pain Medicine, 2021, 22, 1850-1856.	1.9	3
108	Higher buccal mitochondrial DNA and mitochondrial common deletion number are associated with markers of neurodegeneration and inflammation in cerebrospinal fluid. Journal of NeuroVirology, 2022, 28, 281-290.	2.1	3

#	Article	IF	Citations
109	Measures of Physical and Mental Independence Among HIV-Positive Individuals: Impact of Substance Use Disorder. AIDS Research and Human Retroviruses, 2017, 33, 1048-1055.	1.1	2
110	Reply to Haddow, et al.. Clinical Infectious Diseases, 2015, 60, 1442-3.	5.8	0
111	Detection of misfolded protein aggregated in HIVâ€infected people. Alzheimer's and Dementia, 2020, 16, e044336.	0.8	0